Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
No risks detected for PK5 from our risk checks.
Reasonable growth potential with worrying balance sheet.
Share Price & News
How has Basilea Pharmaceutica's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PK5 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PK5 underperformed the German Biotechs industry which returned 5.3% over the past year.
Return vs Market: PK5 underperformed the German Market which returned 17.1% over the past year.
Price Volatility Vs. Market
How volatile is Basilea Pharmaceutica's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Basilea Pharmaceutica undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: PK5 (€32.28) is trading above our estimate of fair value (€11.85)
Significantly Below Fair Value: PK5 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PK5 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PK5 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PK5's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PK5 has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.
How is Basilea Pharmaceutica forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PK5 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: PK5 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PK5's is expected to become profitable in the next 3 years.
Revenue vs Market: PK5's revenue (16.6% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: PK5's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PK5's Return on Equity is forecast to be high in 3 years time
How has Basilea Pharmaceutica performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PK5 is currently unprofitable.
Growing Profit Margin: PK5 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PK5 is unprofitable, but has reduced losses over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare PK5's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PK5 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: PK5's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Basilea Pharmaceutica's financial position?
Financial Position Analysis
Short Term Liabilities: PK5 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PK5 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PK5 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PK5's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: PK5 has a low level of unsold assets or inventory.
Debt Coverage by Assets: PK5 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PK5 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PK5 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Basilea Pharmaceutica's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PK5's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PK5's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PK5's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PK5's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: PK5 is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PK5's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Veitch (54yo)
Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch served as the Pres ...
CEO Compensation Analysis
Compensation vs Market: David 's total compensation ($USD1.52M) is above average for companies of similar size in the German market ($USD817.80K).
Compensation vs Earnings: Insufficient data to compare David 's compensation with company performance.
|Chief Executive Officer||1.4yrs||CHF1.51m||0.012% CHF51.9k|
|Chief Financial Officer||0.4yrs||no data||0.0047% CHF20.0k|
|Chief Scientific Officer||10.7yrs||no data||0.0047% CHF20.0k|
|Chief Medical Officer||1.7yrs||no data||no data|
|Chief Technology Officer||1.3yrs||no data||no data|
|Head of Corporate Communications & Investor Relations||0yrs||no data||no data|
|General Counsel & Corporate Secretary||2.1yrs||no data||no data|
|Head of Global Human Resources||2.7yrs||no data||no data|
|Head of Regulatory Affairs||13.7yrs||no data||no data|
|Head of Internal Services||0yrs||no data||no data|
Experienced Management: PK5's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
|Non-Executive Director||2.4yrs||CHF186.88k||no data|
|Non-Executive Director||6.4yrs||CHF231.90k||no data|
|Director||1.4yrs||no data||0.072% CHF309.3k|
|Non-Executive Director||11.5yrs||CHF190.82k||no data|
Experienced Board: PK5's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Basilea Pharmaceutica AG's company bio, employee growth, exchange listings and data sources
- Name: Basilea Pharmaceutica AG
- Ticker: PK5
- Exchange: DB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF464.645m
- Listing Market Cap: CHF428.459m
- Shares outstanding: 10.74m
- Website: https://www.basilea.com
Number of Employees
- Basilea Pharmaceutica AG
- Grenzacherstrasse 487
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BPMU.F||OTCPK (Pink Sheets LLC)||Yes||Registered Shares||US||USD||Mar 2004|
|BSLN||SWX (SIX Swiss Exchange)||Yes||Registered Shares||CH||CHF||Mar 2004|
|PK5||DB (Deutsche Boerse AG)||Yes||Registered Shares||DE||EUR||Mar 2004|
|0QNA||LSE (London Stock Exchange)||Yes||Registered Shares||GB||CHF||Mar 2004|
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand. The company also provides ceftobiprole, an intravenous antibiotic for the treatment of adult patients with community and hospital-acquired pneumonia, excluding ventilator-associated pneumonia under the Zevtera name in European and various non-European countries. In addition, it engages in developing Derazantinib, an orally administered small molecule inhibitor, which is in a clinical study for the treatment intrahepatic cholangiocarcinoma, a form of biliary tract cancer; BAL101553, a tumor checkpoint controller drug for tumor types unresponsive to standard therapeutics; and BAL3833, an orally available small-molecule drug candidate for use as a panRAF/SRC kinase inhibitor targeting cell signaling pathways. The company was founded in 2000 and is headquartered in Basel, Switzerland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/25 20:35|
|End of Day Share Price||2019/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.